Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

Size: px
Start display at page:

Download "Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director"

Transcription

1 Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director

2 JHMI Patient Population Adults Peds NMDP data >20,000 HSCT

3 JHMI HSCT Protocols Bone marrow (BMT) Mobilized peripheral blood (MPB) Double Cord Blood Units One haplotype matched* Donor Lymphocyte infusion (DLI)* * Non-myeloablative ( mini ) conditioning

4 Why Non-myeloablative? Permits transplantation of older patients Full marrow ablation is not tolerated well by adults due to other medical problems May be used for pre-transplant conditioning for bone marrow or mobilized peripheral blood transplants Also used for alternate protocols One haplotype matched Donor lymphocyte infusion

5 Myeloablative and Non-myeloablative HSCT Myeloablative: Intensive chemotherapy and irradiation Engraftment of HSCT is critical for patient survival Immunosuppression for GVHD. Non-myeloablative: Reduced chemotherapy, low dose irradiation Pre-Tx treatment necessary for engraftment Post-Tx immunosuppression controls rejection and GVHD.

6 JHMI Mini - Haplotype Matched Protocol Conditioning Regimen Dose level 2

7 Why Partial, One Haplotype Matches? Graft versus Leukemia (GVL) Effect Weiden, et al., N Engl J Med 304:1529, 1981 Patients with some GVHD have lower incidence of disease relapse One-haplotype donors selected to maximize GVL in mini haplotype and DLI protocols

8 Mobilized Peripheral Blood MPB) and Donor Lymphocyte Infusion (DLI) CD34+ stem cells mobilized in donor ± T cell depletion Variable periods of mixed chimerism Post-Transplant donor leukocyte infusions may be necessary for full donor chimerism Shlomchik WD. Nat Rev. 2007;7:

9 Adult HLA Matching Requirements BMT or MPB related or unrelated donor Allele level match at HLA-A,B,Cw, DRB1, DQB1 (10/10) Mini Haplotype Donors selected to minimize HLA mismatch in hostversus-graft (HVG) direction; haplotype mm for GVL Donor lymphocyte infusion Donor must be mismatched for 2 or 3 alleles (A,B, DRB1) Preference for DRB1 mismatch in GVH direction

10 Pediatric HSCT Protocols: Matching Requirements Bone marrow HLA identical sibling preferred Fully matched unrelated donor 1 or 2 allele mismatch, related donor 1 or 2 allele mismatch, unrelated donor Mobilized peripheral blood Same as for bone marrow Double Cord blood Minimally matched at 4/6 antigens (A,B, DRB1) Must share at least 1 DRB1, allele ( full match preferred) Same criteria for adults (to 55 yo)

11 The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. Kids are tough! They can tolerate full bone marrow ablation and partial HLA mismatches!

12 Histocompatibility Assessment HLA Typing Related donors :HLA ID vs. 1 haplotype Unrelated: NMDP Requirements for CT Antibody Screening and Crossmatching All unrelated donors All mismatched D:R pairs KIR typing primarily for research

13 Histocompatibility Assessment: HLA Typing Considers level of resolution needed Related donors Low resolution may be sufficient if genotyping possible High resolution needed for two siblings - for possible recombinant haplotypes Unrelated: NMDP Requirements for CT High resolution: HLA-A,B,C,DRB1, DQB1 Once selected all D:R pairs typed for HLA- A,B,Cw, DRB1, DQB1, DPB1 alleles

14 Typing Methods Low-Intermediate resolution Reverse SSOP/Luminex platform (One Lambda, Inc). Local serologic typing trays for back-up and confirmation of expression. High resolution Sequence based typing (SBT) Atria Genetics HLA-B and DRB1 kits Local HLA-A, Cw and DQB1 reagents

15 Typing Ambiguities!!! As of 07/11/08: HLA class I alleles 2215 HLA class II alleles 986

16 Ambiguity Resolution Integration of data from other test methods. SSOP hybridization patterns Genotyping data when available Additional testing with different amplicons and/or probes. Extension of sequence tested, eg. portions of introns or exon 4 for class I Allele separation with group specific primers, followed by sequencing of amplicons Cloning or other separation methods for hemizygous typing

17 Typing Protocol: HLA-Identical Siblings Pt + Family Members Limited family (genotyping not possible) Allele level typing of HLA-A, B,Cw, DRB1; DQ allele group level, unless higher resolution needed Sufficient family for genotyping Low resolution typing class I (A,B,Cw) Potential HLA-ID sibs Typing for class II (DR,DQ) 2 or more HLA-ID donors HLA-DP typing Possible Recombinants (parent homozygous at 1+ loci) - Allele level typing

18 HLA Typing: Unrelated Donors Patients: Allele level - HLA-A,B,C, DRB1 Allele groups DQB1 (unless needed as tie breaker) Donors: Allele level - HLA-A,B,C, DRB1 Allele groups DQB1 (unless needed as tie breaker) HLA-DP typing: Decision among multiple donors Risk factor for GVHD 1 MM increased GVL benefit 1 1 Shaw BE, et al., Clinical Importance of HLA-DPB1 in HSCT, Tissue Antigens; 69 (S1):36-41

19 Pending NMDP Confirmatory Typing Requirements Must perform high resolution typing for common, well documented alleles (CWD)* Do not have to resolve CWD alleles that have identical sequences in antigen recognition site Must test for 3 common null alleles A*2409N exon 4 B*5111N exon 4 Cw*0409N exon 7 * Cano P,et al. Common and well documented alleles: Report of the ad-hoc committee of the ASHI. Human Immunol 2007; 68:

20 Strategy to Resolve Cw*040101/0409N Ambiguity Requires full length (3416bp) amplicon 5 UTR through 3 UTR Previous Cw typing only exons 2,3 sequenced; Cw*0409N requires exon 7 Amplicon length requires different DNA polymerase: GeneAmp High Fidelity enzyme mix (Applied Biosystems) Designed 12 sequencing primer mixes for exons 1,2,3,4,5,6,7 To reduce cost, single direction sequencing for exons 1(reverse), 4-7 (forward); bidirectional for exons 2,3.

21 Locus and Group Specific Amplification Loci Exons Seq Direction Supplier A 2,3,4 Bi-directional Local A2 2,3 Single Direction Local B 2,3,4 Bi-directional Commercial B-TA 2,3 Single Direction Local Cw 2,3 Bi-directional Local 1,4,5,6,7 Single Direction

22 HLA- Haplo ID Donors Pt and Potential Donors Low Resolution Typing Class I Class I Haplo ID Donors Low resolution Typing class II Donor Selection Best match to minimize rejection Pt and Donor Allele level typing HLA-A,B,Cw,DRB1 Allele group typing DQB1, DPB1

23 Antibody Testing: HSCT and Transfusion Support Hemapheresis/Transfusion Support Quick Screen run weekly Emergent samples, as needed AB identification on all + samples HSCT Candidates Screened monthly until TX Donors screened once selected AB identification on all + samples

24 Crossmatches: HSCT Timing Preliminary with donor evaluation Final within one week of TX Types and Methods Forward and reverse Autologous Virtual Xms in some cases

25 Antibody Testing: Methods Screening Pooled antigen/luminex platform (Tepnel, Inc) Pooled and single phenotypes/microarray chip (Invitrogen, Inc.) CDC panel (40-60 cells) Measure of AB titer Detection of IgM and auto-abs Antibody Identification Class I, II phenotype panels/ Luminex (Tepnel) Single antigen beads/ Luminex (One Lambda, Inc)

26 Risk of Graft Failure with a Positive Crossmatch 13/21 31/501 0/6 Mickelson, et al. Clin Transplants 2002.

27 Humoral Sensitization: Haplo ID Donors AB screens Pt and donor AB screen+ AB ID for DSA Pre-TX CDC Crossmatch (XM) XM+ and/or DSA + XM - and DSA - Evaluate other donors or Alternate treatment Post TX AB monitoring Suggested intervals: 1-2 months, or for suspected engraftment failure

28 Humoral Sensitization: Unrelated Donors Patient and Potential Donor Screened for HLA specific Antibodies (HLA-A,B,Cw,DR,DQ, DP) Pre TX CDC XM DP Antibody % or more of D:R pairs matched for 10/10 alleles (A,B,Cw,DRB1,DQB1) will likely be mismatched for at least 1 DP allele. Shaw, et al D:R pairs 54% mm for 1 allele 32% mm for 2 alleles

29 Humoral Sensitization: HLA-ID Sib Pairs Patient and Potential Donor Screened for HLA specific Antibodies (HLA-A,B, Cw, DR, DQ, DP) CDC XM for Highly sensitized Pts DP mm +, DP Antibody+ These options may be useful as decision factor if more than 1 donor is possible.

30 The Best Outcome!!

The Human Major Histocompatibility Complex

The Human Major Histocompatibility Complex The Human Major Histocompatibility Complex 1 Location and Organization of the HLA Complex on Chromosome 6 NEJM 343(10):702-9 2 Inheritance of the HLA Complex Haplotype Inheritance (Family Study) 3 Structure

More information

Documentation of Changes to EFI Standards: v 5.6.1

Documentation of Changes to EFI Standards: v 5.6.1 Modified Standard B - PERSONNEL QUALIFICATIONS B1.000 The laboratory must employ one or more individuals who meet the qualifications and fulfil the responsibilities of the Director/Co-Director, Technical

More information

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie

More information

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS

DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS DEFINITIONS OF HISTOCOMPATIBILITY TYPING TERMS The definitions below are intended as general concepts. There will be exceptions to these general definitions. These definitions do not imply any specific

More information

6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?

6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD? 6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.

More information

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Alison Logan Transplantation Laboratory Manchester Royal Infirmary Haematopoietic progenitor cell transplants

More information

21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com

21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com Transplant Webinar Series: Ep. 6 Donor Selection for Haematopoietic Stem Cell Transplantation Future Webinars The Role of NGS in the Transplant Setting Featuring Dr Sujatha Krishnakumar Sirona Genomics,

More information

New trends in donor selection in Europe: "best match" versus haploidentical. Prof Jakob R Passweg

New trends in donor selection in Europe: best match versus haploidentical. Prof Jakob R Passweg New trends in donor selection in Europe: "best match" versus haploidentical Prof Jakob R Passweg HSCT change in donor type: 1990-2015 9000 H S C T 8000 7000 6000 5000 4000 HLA identical sibling/twin Haplo-identical

More information

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,

More information

MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH

MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH TEJASWINI M. DHAWALE, M.D. HEME FELLOWS CONFERENCE NOVEMBER 08, 2013 CASE PRESENTATION 51 yo M with history of MDS (unilinear

More information

Basel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva

Basel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity

More information

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex

25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD

More information

Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005)

Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005) Completing the CIBMTR Confirmation of HLA Typing Form (Form 2005) Stephen Spellman Research Manager NMDP Scientific Services Maria Brown Scientific Services Specialist Data Management Conference 2007 1

More information

Haplo vs Cord vs URD Debate

Haplo vs Cord vs URD Debate 3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor

More information

Related haploidentical donors versus matched unrelated donors

Related haploidentical donors versus matched unrelated donors Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching

More information

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related or matched unrelated donors Immunobiology Working Committee PIs: Peter Shaw and

More information

Human Leukocyte Antigens and donor selection

Human Leukocyte Antigens and donor selection Human Leukocyte Antigens and donor selection Duangtawan Thammanichanond, MD. PhD. Histocompatibility and Immunogenetics Laboratory, Faculty of Medicine Ramathibodi Hospital, Mahidol University Outline

More information

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient 1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical

More information

HLA Mismatches. Professor Steven GE Marsh. Anthony Nolan Research Institute EBMT Anthony Nolan Research Institute

HLA Mismatches. Professor Steven GE Marsh. Anthony Nolan Research Institute EBMT Anthony Nolan Research Institute HLA Mismatches Professor Steven GE Marsh HLA Mismatches HLA Genes, Structure, Polymorphism HLA Nomenclature HLA Mismatches in HSCT Defining a mismatch HLA Mismatches HLA Genes, Structure, Polymorphism

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.

More information

Specimen Collection Requirements. Test Name Specimen Type Storage Time Storage Conditions

Specimen Collection Requirements. Test Name Specimen Type Storage Time Storage Conditions 1 Specimen Collection Requirements PURPOSE/PRINCIPLE: To outline proper specimen collection for molecular HLA testing, including tube type, minimum specimen amount, proper tube and requisition labeling,

More information

Transplantation. Immunology Unit College of Medicine King Saud University

Transplantation. Immunology Unit College of Medicine King Saud University Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the

More information

Clinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017

Clinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017 Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD

More information

Virtual Crossmatch in Kidney Transplantation

Virtual Crossmatch in Kidney Transplantation Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU 2018.11.21 All transplant candidates are screened to determine the degree of humoral

More information

Bone Marrow Transplantation and the Potential Role of Iomab-B

Bone Marrow Transplantation and the Potential Role of Iomab-B Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation

More information

10/18/2012. A primer in HLA: The who, what, how and why. What?

10/18/2012. A primer in HLA: The who, what, how and why. What? A primer in HLA: The who, what, how and why What? 1 First recognized in mice during 1930 s and 1940 s. Mouse (murine) experiments with tumors Independent observations were made in humans with leukoagglutinating

More information

How to Find an Unrelated Donor Theory & Technology

How to Find an Unrelated Donor Theory & Technology How to Find an Unrelated Donor Theory & Technology Carlheinz R. Müller Zentrales Knochenmarkspender-Register für die Bundesrepublik Deutschland (ZKRD) Ulm, Germany How to Find an Unrelated Donor HLA-Basics

More information

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant

More information

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell

More information

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

Transplant Booklet D Page 1

Transplant Booklet D Page 1 Booklet D Pretest Correct Answers 4. (A) is correct. Technically, performing a hematopoietic stem cell transplant is one of the simplest transplantation procedures. The hematopoietic stem cells are infused

More information

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize

More information

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC

More information

National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants

National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants Biology of Blood and Marrow Transplantation 9:610-615 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0910-0003$30.00/0 doi:10.1016/s1083-8791(03)00329-x National Marrow

More information

What s a Transplant? What s not?

What s a Transplant? What s not? What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence

More information

HLA and new technologies. Vicky Van Sandt

HLA and new technologies. Vicky Van Sandt HLA and new technologies. Vicky Van Sandt Life-threatning malignant and non malignant blood disorders can be cured by hematopoetic stem cell transplantation (HSCT). GVHD is the 2nd most prevalent cause

More information

T cell manipulation of the graft: Yes

T cell manipulation of the graft: Yes T cell manipulation of the graft: Yes J.H. Frederik Falkenburg Department of Hematology L M U C Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for non-malignant disorders: no need for anti-tumor

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001

More information

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin Glossary of Terms This appendix is divided into two sections. The first section, General Terms, defines terms used throughout the CIBMTR data collection forms. The second section, FormsNet TM 2 Terms,

More information

Reduced-intensity Conditioning Transplantation

Reduced-intensity Conditioning Transplantation Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

EBMT2008_1_21:EBMT :06 Pagina 46 * CHAPTER 3. Immunogenetics of allogeneic HSCT * 3.1. The role of HLA in HSCT. J.M.

EBMT2008_1_21:EBMT :06 Pagina 46 * CHAPTER 3. Immunogenetics of allogeneic HSCT * 3.1. The role of HLA in HSCT. J.M. EBMT2008_1_21:EBMT2008 6-11-2008 9:06 Pagina 46 * CHAPTER 3 Immunogenetics of allogeneic HSCT * 3.1 The role of HLA in HSCT J.M. Tiercy EBMT2008_1_21:EBMT2008 6-11-2008 9:06 Pagina 47 CHAPTER 3.1 HLA and

More information

16/01/2018. Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation

16/01/2018. Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation Dr UMA KANGA Dept. of Transplant Immunology & Immunogenetics umakanga@hotmail.com January 2018 Bone

More information

Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation

Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation Pre-Transplant Immunogenetic and Immunological assessment for Hematopoietic Stem Cell Transplantation Dr UMA KANGA Dept. of Transplant Immunology & Immunogenetics umakanga@hotmail.com January 2018 1 Bone

More information

The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK

The MHC and Transplantation Brendan Clark. Transplant Immunology, St James s University Hospital, Leeds, UK The MHC and Transplantation Brendan Clark Transplant Immunology, St James s University Hospital, Leeds, UK Blood Groups Immunofluorescent staining has revealed blood group substance in the cell membranes

More information

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014 Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of

More information

CHAPTER 2 PROTOCOL DESIGN

CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN 2.1 ELIGIBILITY CRITERIA Participants fulfilling the following criteria will be eligible for enrollment in the protocol: 1. Participant is diagnosed

More information

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates

More information

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:

More information

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Rob Wynn RMCH & University of Manchester, UK. HCT in Children Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action

More information

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant

More information

Pilot on inclusion of a case report in the external proficiency testing program

Pilot on inclusion of a case report in the external proficiency testing program Pilot on inclusion of a case report in the external proficiency testing program Sebastiaan Heidt Eurotransplant Reference Laboratory ET EXTRA MURAL MEETING 2016 Background At the extramural meeting 2015

More information

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow 5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL

More information

Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos

Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:

More information

ASHI Proficiency Testing Program Summary Report. Survey 2013-HT1 / HLA Typing

ASHI Proficiency Testing Program Summary Report. Survey 2013-HT1 / HLA Typing ASHI Proficiency Testing Program Summary Report Survey 2013-HT1 / HLA Typing Shipping Date: February 26,2013 / Results Due Date:April 5,2013 / Report Date: May 17,2013 The ASHI HT proficiency testing survey

More information

CHAPTER 3 LABORATORY PROCEDURES

CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified

More information

Allele and Haplotype Frequencies of Human Leukocyte Antigen-A, -B, -C, -DRB1, and -DQB1 From Sequence- Based DNA Typing Data in Koreans

Allele and Haplotype Frequencies of Human Leukocyte Antigen-A, -B, -C, -DRB1, and -DQB1 From Sequence- Based DNA Typing Data in Koreans Original Article Diagnostic Immunology Ann Lab Med 2015;35:429-435 http://dx.doi.org/10.3343/alm.2015.35.4.429 ISSN 2234-3806 eissn 2234-3814 Allele and Haplotype Frequencies of Human Leukocyte Antigen-A,

More information

HISTOCOMPATIBILITY LABORATORIES

HISTOCOMPATIBILITY LABORATORIES HISTOCOMPATIBILITY LABORATORIES SERVICE PROVISION USER GUIDE DOC45 Version 004 September 2015 Page 1 of 23 CONTENTS CONTENTS... 1 SERVICE PROVISION INTRODUCTION... 3 SUMMARY... 4 PROCEDURES UNDERTAKEN

More information

Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale

Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale Management of platelet refractory patients, why does your patient keep on bleeding? Dr Colin Brown, H&I Dept, NHSBT Colindale Pooled Platelets (Buffy Coat Derived) Adult dose from 4 ABO-identical donors

More information

Introduction to Hematopoietic Stem Cell Transplantation

Introduction to Hematopoietic Stem Cell Transplantation Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_acute_myeloid_leukemia

More information

HISTOCOMPATIBILITY LABORATORIES

HISTOCOMPATIBILITY LABORATORIES HISTOCOMPATIBILITY LABORATORIES SERVICE PROVISION USER GUIDE Page 1 of 22 CONTENTS SERVICE PROVISION INTRODUCTION... 3 SUMMARY... 4 PROCEDURES UNDERTAKEN FOR HAEMATOPOIETIC STEM CELL TRANSPLATATION...

More information

Evaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group

Evaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,

More information

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang

More information

2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center

2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,

More information

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017 Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell Ann Haight, MD 9 Sept 2017 Spoiler alert Yes (we have a cure) And No Work to do! 2 Sickle Cell Treatment Options Supportive Care

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_autoimmune_diseases

More information

HLA-A * L

HLA-A * L What is Nomenclature? HLA Nomenclature 3.0 Signifies DNA Subtype Differences outside the coding region (introns) HLA-A * 4 0 01 0 L Steve Spellman Sr. Manager, NMDP Asst. Scientific Director, CIBMTR Locus

More information

Impatto clinico nel trapianto allogenico da donatori non familiari dei mismatch al locus HLA-DPB1

Impatto clinico nel trapianto allogenico da donatori non familiari dei mismatch al locus HLA-DPB1 Impatto clinico nel trapianto allogenico da donatori non familiari dei mismatch al locus HLA-DPB1 Gruppo Italiano Trapianto Midollo Osseo Italian Bone Marrow Donor Registry Immunogenetics and HSCT Units

More information

OPTN/UNOS Policy Notice Review of HLA Tables (2016)

OPTN/UNOS Policy Notice Review of HLA Tables (2016) Review of HLA Tables (2016) Sponsoring Committee: Policy/Bylaws Affected: Histocompatibility Policy 4.10 (Reference Tables of HLA Antigen Values and Split Equivalences) Public Comment: July 31, 2017 October

More information

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1 Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,

More information

XIV. HLA AND TRANSPLANTATION MEDICINE

XIV. HLA AND TRANSPLANTATION MEDICINE XIV. HLA AND TRANSPLANTATION MEDICINE A. Introduction 1. The HLA system includes a complex array of genes and their molecular products that are involved in immune regulation and cellular differentiation.

More information

HLA AND KIR GENE POLYMORPHISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

HLA AND KIR GENE POLYMORPHISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM THE DEPARTMENT OF LABORATORY MEDICINE, DIVISION OF CLINICAL IMMUNOLOGY KAROLINSKA INSTITUTET, STOCKHOLM, SWEDEN HLA AND KIR GENE POLYMORPHISM IN HEMATOPOIETIC STEM CELL TRANSPLANTATION Marie Schaffer

More information

The Use of HLA /HPA Selected Platelets

The Use of HLA /HPA Selected Platelets The Use of HLA /HPA Selected Platelets Dr Colin Brown PhD FRCPath. Consultant Clinical Scientist Histocompatibility and Immunogenetics HLA and Transfusion Human Leucocyte Antigens HLA Human Platelet Antigens

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description

More information

Calculation Tables. Olerup SSP Kits without Taq Polymeras

Calculation Tables. Olerup SSP Kits without Taq Polymeras Calculation Tables lerup SSP Kits without Taq Polymeras Table 1: Volumes of the components needed per test for different numbers of when using Master Mix without. The recommended volumes listed below include

More information

Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation

Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation AACC Professional Course BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation J. Ryan

More information

Mary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT. 4th April 2014

Mary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT. 4th April 2014 Solid Organ Transplantation How the Lab Contributes to Improved Patient Outcomes Mary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT 4th April 2014 Solid Organ Transplantation

More information

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

More information

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475

More information

Calculation Tables. Olerup SSP Kits without Taq Polymeras

Calculation Tables. Olerup SSP Kits without Taq Polymeras Calculation Tables lerup SSP Kits without Polymeras Table 1: Volumes of the components needed per test for different numbers of when using Master Mix without. The recommended volumes listed below include

More information

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

2017 BANFF-SCT Joint Scientific Meeting. BARCELONA March 2017

2017 BANFF-SCT Joint Scientific Meeting. BARCELONA March 2017 2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 Adriana Zeevi PhD (D) ABHI Professor of Pathology, Surgery and Immunology Director of Histocompatibility Laboratory University of Pittsburgh

More information

Samples Available for Recipient and Donor

Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,

More information

Does NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia

Does NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia Does NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia Recognition of missing self HLA triggers lysis NK Inhibitory receptor Activating

More information

Dedicated to Gordon. Stem Cell Transplantation: The Journey

Dedicated to Gordon. Stem Cell Transplantation: The Journey Dedicated to Gordon Stem Cell Transplantation: The Journey 1949 Jacobson et al: Radioprotection by lead shielding of the spleen of a lethally irradiated animal 1951 Lorenz et al: Radiation protection

More information

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte

More information

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1. Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic

More information

ABO INCOMPATILIBITY AND TRANSPLANTATION

ABO INCOMPATILIBITY AND TRANSPLANTATION ABO INCOMPATILIBITY AND TRANSPLANTATION Aleksandar Mijovic Consultant Haematologist/Senior Lecturer King s College Hospital/NHS Blood and Transplant London, UK RTC Edu Meeting May 2017 ABO antigens Expressed

More information

Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche

Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Massimo Fabrizio Martelli Ematologia ed Immunologia Clinica Università degli Studi di Perugia 41 Congresso Nazionale

More information

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation for Severe Aplastic Anemia Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center

More information

EBV in HSCT 2015 update of ECIL guidelines

EBV in HSCT 2015 update of ECIL guidelines ECIL-6 EBV in HSCT 2015 update of ECIL guidelines Jan Styczynski (Poland, chair), Walter van der Velden (Netherlands), Christopher Fox (United Kingdom), Dan Engelhard (Israel), Rafael de la Camara (Spain),

More information

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section: Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:

More information

Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( )

Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( ) TRANSPLANTATION Allogeneic hematopoietic stem cell transplantation from family members other than -identical siblings over the last decade (1991-2000) Yoshinobu Kanda, Shigeru Chiba, Hisamaru Hirai, Hisashi

More information

Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH

Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH Tzu-Ting Chen, Wen-Jyi Lo, Chiao-Lin Lin, Ching-Chan Lin, Li-Yuan Bai, Supeng Yeh, Chang-Fang Chiu Hematology and

More information

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare

More information